Fate Therapeutics Inc (FATE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Fate Therapeutics Inc (FATE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH137961D
  • |
  • Pages: 79
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Fate Therapeutics Inc (Fate Therapeutics) is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders. The company's pipeline product candidates include cellular immunotherapy pipeline, immuno-oncology candidates, and immuno-regulatory candidates. Its immuno-oncology product candidates include adaptive NK, pluripotent cell-derived cancer immunotherapies, and engineered CAR and TCR T- cell immunotherapies. Its products are derived from pluripotent cells. Fate Therapeutics uses ex vivo cell programming approach to include cell-surface proteins, rapid and supra-physiologic activation or inhibition of therapeutically-relevant genes, and to regulate the therapeutic function. The company's immuno-regulatory cellular therapies promote immune system homeostasis for patients undergoing hematopoietic cell transplantation and immune disorders. Fate Therapeutics is headquartered in San Diego, California, the US.

Fate Therapeutics Inc (FATE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Fate Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Fate Therapeutics Raises USD8 Million in Venture Financing 12

Fate Therapeutics Raises USD 20 Million In Venture financing 13

Fate Therapeutics Raises USD 9.2 Million In Venture financing 14

Partnerships 15

Fate Therapeutics Enters into Agreement with ONO Pharma 15

Fate Therapeutics Enters into Partnership with University of California San Diego 16

Fate Therapeutics Expands Research Agreement with Regents of the University of Minnesota 17

Fate Therapeutics Enters into Research Agreement with Boston Children's Hospital 18

Licensing Agreements 19

Fate Therapeutics Enters into License Agreement with Gladstone Institutes 19

Fate Therapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 20

Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 22

Fate Therapeutics Enters into Licensing Agreement with Board of Trustees of the Leland Stanford Junior University 24

Equity Offering 25

Fate Therapeutics Raises USD143.8 Million in Public Offering of Shares 25

Fate Therapeutics Raises USD46 Million in Public Offering of Shares 27

Fate Therapeutics to Raise Funds through Public Offering of Shares 29

Fate Therapeutics to Raise USD37.5 Million in Private Placement of Preferred Stock 30

Fate Therapeutics to Raise USD19.3 Million in Private Placement of Shares 32

Fate Therapeutics Plans to Raise up to USD12.4 Million in Public Offering of Shares 34

Fate Therapeutics Raises USD10.3 Million in Private Placement of Shares 35

Fate Therapeutics Raises USD34.5 Million in Public Offering of Shares 36

Fate Therapeutics Completes IPO For USD 46 Million 38

Fate Therapeutics Inc-Key Competitors 39

Fate Therapeutics Inc-Key Employees 40

Fate Therapeutics Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 42

Financial Announcements 42

Nov 01, 2018: Fate Therapeutics reports third quarter 2018 financial results and highlights operational progress 42

Aug 06, 2018: Fate therapeutics announces second quarter 2018 financial results and highlights operational progress 44

May 10, 2018: Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress 46

Mar 05, 2018: Fate Therapeutics Announces Fourth Quarter 2017 Financial Results 48

Nov 01, 2017: Fate Therapeutics Reports Third Quarter 2017 Financial Results 50

Aug 14, 2017: Fate Therapeutics Reports Second Quarter 2017 Financial Results 52

May 15, 2017: Fate Therapeutics Reports First Quarter 2017 Financial Results 54

Mar 16, 2017: Fate Therapeutics Reports Fourth Quarter 2016 Financial Results 56

Corporate Communications 58

Oct 04, 2018: Fate Therapeutics names Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations 58

Sep 14, 2017: Fate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development 59

Product News 60

12/11/2017: Fate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling Manufacture of FT500 60

12/09/2017: Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8a+ T Cells from Clonal Engineered Master Pluripotent Cell Line for Off-the-Shelf T-cell Immunotherapy 61

05/10/2017: Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 in Advanced Solid Tumors 62

03/13/2017: Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy 63

02/23/2018: Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy 64

Clinical Trials 65

Apr 16, 2018: Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual Meeting Press Program 65

Mar 29, 2018: Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018 66

Mar 19, 2018: Fate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune 67

Feb 20, 2018: Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors 68

Dec 11, 2017: Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune and Initiation of Phase 2 Stage 70

Dec 08, 2017: Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer 72

Nov 10, 2017: Fate Therapeutics Announces Initial Clinical Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for Relapsed / Refractory Acute Myelogenous Leukemia at SITC 2017 Annual Meeting 73

Nov 01, 2017: Fate Therapeutics Will Present Clinical Data From PROTECT Study of ProTmune at 2017 ASH Annual Meeting 75

Sep 18, 2017: Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune for Prevention of Acute Graft-versus-Host Disease 76

Aug 08, 2017: Fate Therapeutics Announces Publication of Preclinical Data in Cancer Research and FDA Clearance of Third IND for FATE-NK100 77

Jan 05, 2017: Fate Therapeutics Announces First Patient Treated in ProTmune PROTECT Clinical Trial for the Prevention of Graft-Versus-Host Disease 78

Appendix 79

Methodology 79

About GlobalData 79

Contact Us 79

Disclaimer 79

List of Figures

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Fate Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Fate Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Fate Therapeutics Raises USD8 Million in Venture Financing 12

Fate Therapeutics Raises USD 20 Million In Venture financing 13

Fate Therapeutics Raises USD 9.2 Million In Venture financing 14

Fate Therapeutics Enters into Agreement with ONO Pharma 15

Fate Therapeutics Enters into Partnership with University of California San Diego 16

Fate Therapeutics Expands Research Agreement with Regents of the University of Minnesota 17

Fate Therapeutics Enters into Research Agreement with Boston Children's Hospital 18

Fate Therapeutics Enters into License Agreement with Gladstone Institutes 19

Fate Therapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 20

Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 22

Fate Therapeutics Enters into Licensing Agreement with Board of Trustees of the Leland Stanford Junior University 24

Fate Therapeutics Raises USD143.8 Million in Public Offering of Shares 25

Fate Therapeutics Raises USD46 Million in Public Offering of Shares 27

Fate Therapeutics to Raise Funds through Public Offering of Shares 29

Fate Therapeutics to Raise USD37.5 Million in Private Placement of Preferred Stock 30

Fate Therapeutics to Raise USD19.3 Million in Private Placement of Shares 32

Fate Therapeutics Plans to Raise up to USD12.4 Million in Public Offering of Shares 34

Fate Therapeutics Raises USD10.3 Million in Private Placement of Shares 35

Fate Therapeutics Raises USD34.5 Million in Public Offering of Shares 36

Fate Therapeutics Completes IPO For USD 46 Million 38

Fate Therapeutics Inc, Key Competitors 39

Fate Therapeutics Inc, Key Employees 40

Fate Therapeutics Inc, Subsidiaries 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Fate Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17773
Site License
USD 500 INR 35545
Corporate User License
USD 750 INR 53318

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com